Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma

Huo,Xinying; Zhang,Qi; Liu,Angela  M.; Tang,Cuiju; Gong,Yongling; Bian,Jianmin; Luk,John  M.; Xu,Zhi; Chen,Jinfei

doi:10.3892/or.2012.2176

Overexpression of Yes-associated protein confers doxorubicin resistance in hepatocellullar carcinoma

Authors:
- Xinying Huo
- Qi Zhang
- Angela M. Liu
- Cuiju Tang
- Yongling Gong
- Jianmin Bian
- John M. Luk
- Zhi Xu
- Jinfei Chen
View Affiliations

Affiliations: Department of Oncology, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, P.R. China, Departments of Pharmacology and Surgery, National University of Singapore, 117597 Singapore, Republic of Singapore, Department of General Surgery, Nanjing First Hospital, Nanjing Medical University, Nanjing 210006, P.R. China
Published online on: December 10, 2012 https://doi.org/10.3892/or.2012.2176
Pages: 840-846

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatocellular carcinoma (HCC) is one of the most aggressive malignancies worldwide and is highly resistant to chemotherapy. Yes-associated protein (YAP) is the downstream effector of the Hippo signaling pathway, which is frequently overexpressed in many types of cancers. Amplification of the YAP gene and overexpression of YAP in HCC have previously been reported to contribute to hepatocyte malignant transformation and tumor progression. In this study, we aimed to investigate the potential role of YAP in HCC chemoresistance. Overexpression of YAP resulted in resistance against doxorubicin-induced apoptosis in HCC cell lines, whereas suppression of the endogenous YAP expression by RNA interference demonstrated the reverse effect. Western blotting revealed that, following exposure to doxorubicin, YAP-overexpressing cells exhibited decreased cleaved PARP, increased phosphorylation of Akt and ERK1/2, and elevated Bcl-xL expression in comparison to the vector control. Inhibition of YAP expression sensitized HCC cells to doxorubicin, by exhibiting increased cleaved PARP, decreased levels of phosphorylated Akt, phosphorylated ERK1/2 and Bcl-xL expression. In addition, pretreatment with the MEK1/2 inhibitor U0126 but not the PI3-K inhibitor LY294002 significantly enhanced doxorubicin-induced apoptosis and decreased Bcl-xL expression in YAP-overexpressing HCC cells. Our data provide evidence that overexpression of YAP plays an important role in conferring doxorubicin resistance to HCC, which is at least partially mediated by YAP-induced activation of the MAP kinase pathway. Targeting YAP may be a promising adjunct for overcoming doxorubicin resistance in HCC.

View Figures

View References

1	Meza-Junco J, Montano-Loza AJ, Liu DM, et al: Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how? Cancer Treat Rev. 38:54–62. 2012. View Article : Google Scholar : PubMed/NCBI
2	Huppert P: Current concepts in transarterial chemoembolization of hepatocellular carcinoma. Abdom Imaging. 36:677–683. 2011. View Article : Google Scholar : PubMed/NCBI
3	Llovet JM and Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology. 37:429–442. 2003. View Article : Google Scholar : PubMed/NCBI
4	Asghar U and Meyer T: Are there opportunities for chemotherapy in the treatment of hepatocellular cancer? J Hepatol. 56:686–695. 2012. View Article : Google Scholar : PubMed/NCBI
5	Yin M and Zhang L: Hippo signaling: a hub of growth control, tumor suppression and pluripotency maintenance. J Genet Genomics. 38:471–481. 2012. View Article : Google Scholar : PubMed/NCBI
6	Chan SW, Lim CJ, Chen L, et al: The Hippo pathway in biological control and cancer development. J Cell Physiol. 226:928–939. 2011. View Article : Google Scholar : PubMed/NCBI
7	Zhao B, Li L, Tumaneng K, Wang CY and Guan KL: A coordinated phosphorylation by Lats and CK1 regulates YAP stability through SCF(beta-TRCP). Genes Dev. 24:72–85. 2010. View Article : Google Scholar : PubMed/NCBI
8	Urtasun R, Latasa MU, Demartis MI, et al: Connective tissue growth factor autocriny in human hepatocellular carcinoma: oncogenic role and regulation by epidermal growth factor receptor/yes-associated protein-mediated activation. Hepatology. 54:2149–2158. 2012. View Article : Google Scholar
9	Xu MZ, Chan SW, Liu AM, et al: AXL receptor kinase is a mediator of YAP-dependent oncogenic functions in hepatocellular carcinoma. Oncogene. 30:1229–1240. 2011. View Article : Google Scholar : PubMed/NCBI
10	Zhao B, Wei X, Li W, et al: Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 21:2747–2761. 2007. View Article : Google Scholar : PubMed/NCBI
11	Overholtzer M, Zhang J, Smolen GA, et al: Transforming properties of YAP, a candidate oncogene on the chromosome 11q22 amplicon. Proc Natl Acad Sci USA. 103:12405–12410. 2006. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Su L and Ou Q: Yes-associated protein promotes tumour development in luminal epithelial derived breast cancer. Eur J Cancer. 48:1227–1234. 2012. View Article : Google Scholar : PubMed/NCBI
13	Dong J, Feldmann G, Huang J, et al: Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 130:1120–1133. 2007. View Article : Google Scholar : PubMed/NCBI
14	Zender L, Spector MS, Xue W, et al: Identification and validation of oncogenes in liver cancer using an integrative oncogenomic approach. Cell. 125:1253–1267. 2006. View Article : Google Scholar : PubMed/NCBI
15	Steinhardt AA, Gayyed MF, Klein AP, et al: Expression of Yes-associated protein in common solid tumors. Hum Pathol. 39:1582–1589. 2008. View Article : Google Scholar : PubMed/NCBI
16	Xu MZ, Yao TJ, Lee NP, et al: Yes-associated protein is an independent prognostic marker in hepatocellular carcinoma. Cancer. 115:4576–4585. 2009. View Article : Google Scholar : PubMed/NCBI
17	Liu LX, Lee NP, Chan VW, et al: Targeting cadherin-17 inactivates Wnt signaling and inhibits tumor growth in liver carcinoma. Hepatology. 50:1453–1463. 2009. View Article : Google Scholar : PubMed/NCBI
18	Ikeda M, Okusaka T, Ueno H, et al: Hepatic arterial infusion chemotherapy with epirubicin in patients with advanced hepatocellular carcinoma and portal vein tumor thrombosis. Oncology. 72:188–193. 2007. View Article : Google Scholar : PubMed/NCBI
19	Park SH, Lee Y, Han SH, et al: Systemic chemotherapy with doxorubicin, cisplatin and capecitabine for metastatic hepatocellular carcinoma. BMC Cancer. 6:32006. View Article : Google Scholar : PubMed/NCBI
20	Avila MA, Berasain C, Sangro B and Prieto J: New therapies for hepatocellular carcinoma. Oncogene. 25:3866–3884. 2006. View Article : Google Scholar : PubMed/NCBI
21	Park JW, Koh YH, Kim HB, et al: Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 56:1336–1342. 2012. View Article : Google Scholar : PubMed/NCBI
22	Wang P, Bai Y, Song B, et al: PP1A-mediated dephosphorylation positively regulates YAP2 activity. PLoS One. 6:e242882011. View Article : Google Scholar : PubMed/NCBI
23	Huang JM, Nagatomo I, Suzuki E, et al: YAP modifies cancer cell sensitivity to EGFR and survivin inhibitors and is negatively regulated by the non-receptor type protein tyrosine phosphatase 14. Oncogene. Jun 11–2012.(Epub ahead of print).
24	Fernandez LA, Squatrito M, Northcott P, et al: Oncogenic YAP promotes radioresistance and genomic instability in medulloblastoma through IGF2-mediated Akt activation. Oncogene. 31:1923–1937. 2012. View Article : Google Scholar : PubMed/NCBI
25	Bao Y, Nakagawa K, Yang Z, et al: A cell-based assay to screen stimulators of the Hippo pathway reveals the inhibitory effect of dobutamine on the YAP-dependent gene transcription. J Biochem. 150:199–208. 2011. View Article : Google Scholar : PubMed/NCBI
26	Shimizu S, Narita M and Tsujimoto Y: Bcl-2 family proteins regulate the release of apoptogenic cytochrome c by the mitochondrial channel VDAC. Nature. 399:483–487. 1999. View Article : Google Scholar : PubMed/NCBI
27	Lee TL, Yeh J, Friedman J, et al: A signal network involving coactivated NF-kappaB and STAT3 and altered p53 modulates BAX/BCL-XL expression and promotes cell survival of head and neck squamous cell carcinomas. Int J Cancer. 122:1987–1998. 2008. View Article : Google Scholar : PubMed/NCBI
28	Basu S, Totty NF, Irwin MS, Sudol M and Downward J: Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14-3-3 and attenuation of p73-mediated apoptosis. Mol Cell. 11:11–23. 2003. View Article : Google Scholar : PubMed/NCBI
29	Lapi E, Di Agostino S, Donzelli S, et al: PML, YAP, and p73 are components of a proapoptotic autoregulatory feedback loop. Mol Cell. 32:803–814. 2008. View Article : Google Scholar : PubMed/NCBI
30	Naci D, El Azreq MA, Chetoui N, et al: α2β1 integrin promotes chemoresistance against doxorubicin in cancer cells through extracellular signal-regulated kinase (ERK). J Biol Chem. 287:17065–17076. 2012.
31	Yang CL, Jiang FQ, Xu F and Jiang GX: ADAM10 overexpression confers resistance to doxorubicin-induced apoptosis in hepatocellular carcinoma. Tumour Biol. 33:1535–1541. 2012. View Article : Google Scholar : PubMed/NCBI
32	Jiao M and Nan KJ: Activation of PI3 kinase/Akt/HIF-1α pathway contributes to hypoxia-induced epithelial-mesenchymal transition and chemoresistance in hepatocellular carcinoma. Int J Oncol. 40:461–468. 2012.
33	Boucher MJ, Morisset J, Vachon PH, Reed JC, Laine J and Rivard N: MEK/ERK signaling pathway regulates the expression of Bcl-2, Bcl-X(L), and Mcl-1 and promotes survival of human pancreatic cancer cells. J Cell Biochem. 79:355–369. 2000. View Article : Google Scholar : PubMed/NCBI